stoxline Quote Chart Rank Option Currency Glossary
  
Dicerna Pharmaceuticals, Inc. (DRNA)
38.22  0 (0%)    12-31 19:00
Open: 38.21
High: 38.24
Volume: 5,540,084
  
Pre. Close: 38.22
Low: 38.21
Market Cap: 0(M)
Technical analysis
2022-02-14 10:19:02 AM
Short term     
Mid term     
Targets 6-month :  44.65 1-year :  44.66
Resists First :  38.22 Second :  38.24
Pivot price 38.22
Supports First :  38.2 Second :  31.79
MAs MA(5) :  38.22 MA(20) :  38.22
MA(100) :  31.45 MA(250) :  29.95
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  33.3 D(3) :  33.3
RSI RSI(14): 81.9
52-week High :  40.13 Low :  19.05
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ DRNA ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Headline News

Tue, 28 Dec 2021
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Business Wire

Thu, 18 Nov 2021
Novo Nordisk to Acquire Dicerna - Business Wire

Thu, 18 Nov 2021
Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today - The Motley Fool

Tue, 02 Nov 2021
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021 - Business Wire

Tue, 12 Oct 2021
How Much Of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Do Institutions Own? - Yahoo Finance

Mon, 24 May 2021
Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 78 (M)
Shares Float 60 (M)
Held by Insiders 7.4 (%)
Held by Institutions 88.5 (%)
Shares Short 4,770 (K)
Shares Short P.Month 2,880 (K)
Stock Financials
EPS -1.63
EPS Est Next Qtrly -0.69
EPS Est This Year -2.71
EPS Est Next Year -2.76
Book Value (p.s.) 1.37
Profit Margin -64.6 %
Operating Margin -62.9 %
Return on Assets (ttm) -10.5 %
Return on Equity (ttm) -95.3 %
Qtrly Rev. Growth 28.7 %
Gross Profit (p.s.) -0.53
Sales Per Share 2.47
EBITDA (p.s.) -1.5
Qtrly Earnings Growth 0 %
Operating Cash Flow 21 (M)
Levered Free Cash Flow -46 (M)
Stock Valuations
PE Ratio -23.45
PEG Ratio 0
Price to Book value 27.69
Price to Sales 15.44
Price to Cash Flow 141.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android